Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fiscal 1990 budget agreement

Executive Summary

Budget bill unanimously adopted by a House/Senate conference committee on May 11 includes $ 100 mil. in "unspecified savings" in health program. Staffers say the line item, adopted from the Senate version, was inspired by the Bush Administration's FDA user fee proposal. However, they note, the savings are "assumed" but not "forced" upon the authorization or appropriations committees. Leaders of both the Senate Labor & Human Resources Committee and the House Energy & Commerce Committee -- including Sens. Kennedy (D-Mass.) and Hatch (R-Utah), and Rep. Waxman (D-Calif.) -- oppose FDA user fees. The budget plan must be approved by the full House and Senate.

You may also be interested in...



Indo-German Collaboration Delivers Novel Diabetic Foot Ulcer Treatment

Centaur-CytoTools introduces novel topical treatment for diabetic foot ulcers in India, for which they see limited direct competition and hope to change the way the difficult-to-treat diabetes complication is managed. Phase III studies are ongoing in Europe.

QUOTED. 1 October 2020. Stephen Hahn.

The head of the US Food and Drug Administration praised the life-saving work of device center staff in response to the coronavirus pandemic.

US FDA Heads Into October With Calm Approvals Forecast

Decision on Regeneron’s Ebola virus therapy, which uses a similar monoclonal antibody cocktail approach as the company’s COVID-19 therapy candidate, stands out among the 10 user fee goal dates in the coming month.

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel